Received Feb 27, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
potential administration after below temperature excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a patient who received HAV (Havrix) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis, HBV (Engerix B) for prophylaxis and Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Havrix, Boostrix, Engerix B and Shingrix. On an unknown date, an unknown time after receiving Havrix, Boostrix, Engerix B and Shingrix, the patient experienced incorrect storage of drug (Verbatim: potential administration after below temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 19-FEB-2026 The batch number was not provided, and we are unable to contact the reporter.
Test Name: temperature; Result Unstructured Data: (Test Result:4.5 celsius,Unit:unknown,Normal Low:,Normal High:) for 8 hours